首页> 美国卫生研究院文献>Memrias do Instituto Oswaldo Cruz >Successful application of virtual screening and molecular dynamicssimulations against antimalarial molecular targets
【2h】

Successful application of virtual screening and molecular dynamicssimulations against antimalarial molecular targets

机译:虚拟筛选和分子动力学的成功应用对抗疟疾分子靶标的模拟

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The main challenge in the control of malaria has been the emergence of drug-resistant parasites. The presence of drug-resistant Plasmodium sp. has raised the need for new antimalarial drugs. Molecular modelling techniques have been used as tools to develop new drugs. In this study, we employed virtual screening of a pyrazol derivative (Tx001) against four malaria targets: plasmepsin-IV, plasmepsin-II, falcipain-II, and PfATP6. The receiver operating characteristic curves and area under the curve (AUC) were established for each molecular target. The AUC values obtained for plasmepsin-IV, plasmepsin-II, and falcipain-II were 0.64, 0.92, and 0.94, respectively. All docking simulations were carried out using AutoDock Vina software. The ligand Tx001 exhibited a better interaction with PfATP6 than with the reference compound (-12.2 versus -6.8 Kcal/mol). The Tx001-PfATP6 complex was submitted to molecular dynamics simulations in vacuum implemented on an NAMD program. The ligand Tx001 docked at the same binding site as thapsigargin, which is a natural inhibitor of PfATP6. Compound TX001 was evaluated in vitro with a P. falciparum strain (W2) and a human cell line (WI-26VA4). Tx001 was discovered to be active against P. falciparum (IC50 = 8.2 µM) and inactive against WI-26VA4 (IC50 > 200 µM). Further ligandoptimisation cycles generated new prospects for docking and biological assays.
机译:控制疟疾的主要挑战是耐药性寄生虫的出现。耐药疟原虫的存在。已经增加了对新抗疟药的需求。分子建模技术已被用作开发新药的工具。在这项研究中,我们针对4个疟疾目标:吡咯菌素IV,纤溶酶II,恶性激素II和PfATP6对吡唑衍生物(Tx001)进行了虚拟筛选。为每个分子靶标建立了受体工作特征曲线和曲线下面积(AUC)。对于纤溶酶-IV,纤溶酶-II和falcipain-II所获得的AUC值分别为0.64、0.92和0.94。所有对接模拟均使用AutoDock Vina软件进行。与参考化合物相比,配体Tx001与PfATP6的相互作用更好(-12.2对-6.8 Kcal / mol)。 Tx001-Pf​​ATP6复合物已提交给在NAMD程序上实施的分子动力学模拟。配体Tx001与thapsigargin结合在相同的结合位点,thapsigargin是PfATP6的天然抑制剂。用恶性疟原虫菌株(W2)和人细胞系(WI-26VA4)在体外评估化合物TX001。发现Tx001对恶性疟原虫有活性(IC50 = 8.2 µM),对WI-26VA4无活性(IC50> 200 µM)。其他配体优化周期为对接和生物学分析产生了新的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号